Linden Advisors’s BridgeBio Pharma BBIO Stock Holding History

Linden Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-47,255	Closed	-$1.37M	–	264
2020 Q1	$1.37M	Buy	+47,255	New	+$1.47M	0.02%	150

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Linden Advisors's BBIO Position: Q2 2020 in Review

Linden Advisors sold out of BridgeBio Pharma (BBIO) in Q2 2020, closing a stake of 47,255 shares — an estimated $1.37M sold.

Linden Advisors first reported a position in BBIO in Q1 2020 and held it in 1 quarter. The position peaked at $1.37M in Q1 2020. 116 funds tracked by Wall St. Rank hold BBIO as of Q2 2020.

Linden Advisors reported no remaining BridgeBio Pharma position as of Q2 2020 after selling out during the quarter.
Linden Advisors sold 47,255 BridgeBio Pharma shares in Q2 2020, an estimated $1.37M.
Linden Advisors first reported a position in BridgeBio Pharma in Q1 2020 and held it in 1 quarter.
Linden Advisors's BridgeBio Pharma position peaked at $1.37M in Q1 2020.
116 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2020.

Based on Linden Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.